P110α

Aug 13, 2020

PIQRAY® is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR-positive, HER2-negative advanced breast cancer

Jun 16, 2020

Identification of Alpelisib (BYL 719) as a Potential Treatment for Endometrial Cancers

Feb 05, 2020

CLOVES Syndrome Community Receives $450,000 Award from Chan Zuckerberg Initiative

Dec 10, 2019

Caris Life Sciences to Present Data Evaluating PI3K Pathway Alterations at the 2019 San Antonio Breast Cancer Symposium (SABCS)

Jul 01, 2019

Global Aliqopa (Copanlisib; Bayer) Drug Profile 2019: A Small Molecule Phosphoinositide 3-Kinase (PI3K) Inhibitor with High Selectivity for the p110-alpha/delta Catalytic Subunits

May 28, 2019

Sysmex Inostics' SafeSEQ ER+/HER2- Breast Cancer Panel Demonstrates Equivalent Sensitivity to OncoBEAM(TM) Enhanced Digital PCR Technology for Detection of Mutations in Circulating Tumor DNA

May 24, 2019

FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer

May 24, 2019

FDA approves first PI3K inhibitor for breast cancer

Apr 02, 2019

Petra Pharma Strengthens Management Team With Recent Leadership Appointments

Dec 06, 2018

Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses